234 completed, 13 terminated, 9 withdrawn, 6 active not recruiting. 102 Not applicable, 64 Phase 3, 42 Phase 2, 42 Phase 4, 20 Phase 1.
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BL1107 Response and Intensity Guided Dosing for Hyperemia Resolution Trial BL1107 - Dry Eye Disease | Phase 2 | Not yet recruiting | Bausch & Lomb Incorporated | 20 | 2026-10-01 | 2026-08-21 |
| BL-RX01-TFSTAB-1402 Determine the ability of the iTrace™, BOSA™, OPD-Scan III, and IDRA to detect tear film stability utilizing Miebo® - Dry Eye | Phase 4 | Recruiting | Vance Thompson Vision | 20 | 2026-08-01 | 2026-08-27 |
| A Study of BL1332 on Capsaicin-Induced Ocular Pain in Healthy Trial Participants BL1332 eye drops, BL1332 Placebo eye drops - Healthy | Phase 1 | Completed | Bausch & Lomb Incorporated | 28 | 2026-07-06 | 2026-09-10 |
| A Single Center, Open-Label Study to Evaluate the Ability of the TearScience™ LipiView™ II Ocular Surface Interferometer and the Keratograph® 5M to Detect Tear Film Stability Utilizing Miebo® Determine the ability of the TearScience™ LipiView™ II Ocular Surface Interferometer and the Keratograph® 5M to detect tear film stability utilizing Miebo® - Dry Eye | Phase 4 | Active not recruiting | The Eye Care Institute | 20 | 2026-06-26 | 2026-07-29 |
| A Multicenter, Open-Label Study to Evaluate Perioperative Treatment of Dry Eye With Miebo® in Subjects Undergoing LASIK Miebo four times per day - Dry Eye Syndrome (DES), Dry Eye Disease (DED) | Phase 4 | Recruiting | Vance Thompson Vision | 100 | 2026-05-05 | 2026-06-24 |
| Efficacy of a Novel Myopia Defocus Spectacle Lens in School-Aged Children BCMC lens - Myopia | Not applicable | Active not recruiting | The Hong Kong Polytechnic University | 50 | 2026-04-10 | 2026-06-03 |
| A Study to Evaluate the Use of Topical Ocular BL1332 for the Management of Postoperative Ocular Pain Following Photorefractive Keratectomy Topical Ocular BL1332 low dose, Topical Ocular BL1332 high dose, BL1332 Vehicle ophthalmic vehicle - Pain, Postoperative | Phase 2 | Not yet recruiting | Bausch & Lomb Incorporated | 123 | 2026-04-01 | 2026-02-17 |
| A Study to Investigate the Safety and Effectiveness of the Technolas® TENEO 317 Model 2 Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Myopia or Myopic Astigmatism TENEO 317 Model 2 (1.28 US) Excimer Laser - Myopic Astigmatism | Not applicable | Not yet recruiting | Bausch & Lomb Incorporated | 32 | 2026-04-01 | 2026-01-30 |
| Revive Toric RWE Study REVIVE samfilcon B custom toric contact lenses - Astigmatism | Withdrawn | Bausch & Lomb Incorporated | 2026-03-01 | 2026-10-16 | ||
| This is a Single Center, Open-label Prospective Study to Evaluate the Effect of Xiidra® (Lifitegrast Ophthalmic Solution 5.0%) on Tear Film Biomarkers in Dry Eye (Xiidra®) Lifitegrast Ophthalmic Solution 5.0% - Ocular Surface Disease, Dry Eye Syndrome (DES) | Phase 4 | Not yet recruiting | Pittsburgh Research Institute | 36 | 2026-03-01 | 2026-03-24 |
| A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease Lifitegrast/perfluorohexyloctane (PFHO) - Dry Eye Disease | Phase 3 | Withdrawn | Bausch & Lomb Incorporated | 2025-12-01 | 2025-12-10 | |
| Effectiveness and Safety of the TENEO 317 Model 2 Excimer Laser to Treat Myopia With or Without Astigmatism by Transepithelial Photorefractive Keratectomy TENEO 317 Model 2 excimer laser - Myopia | Not applicable | Not yet recruiting | Bausch & Lomb Incorporated | 140 | 2025-11-01 | 2025-06-15 |
| Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension BL1107 Low dose, BL1107 High dose, Timolol maleate 0.5% - Glaucoma | Phase 2 | Completed | Bausch & Lomb Incorporated | 252 | 2025-10-24 | 2026-07-22 |
| A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease Lifitegrast/Perfluorohexyloctane Fixed Dose Combination, Lifitegrast, Perfluorohexyloctane - Dry Eye Disease | Phase 2 | Completed | Bausch & Lomb Incorporated | 443 | 2025-10-24 | 2026-07-14 |
| A Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Concentrations of Topical Ocular BL1332 in Healthy Volunteers BL1332 ophthalmic solution, BL1332 ophthalmic vehicle - Ocular Pain | Phase 1 | Active not recruiting | Bausch & Lomb Incorporated | 24 | 2025-07-29 | 2026-01-27 |
| A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear Perfluorohexyloctane ophthalmic solution - Dry Eye | Phase 4 | Completed | Bausch & Lomb Incorporated | 104 | 2025-07-02 | 2025-12-18 |
| A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adult Subjects With Ocular Redness BTOS-HA, Lumify® - Ocular Redness | Phase 3 | Completed | Bausch & Lomb Incorporated | 578 | 2025-05-22 | 2026-05-28 |
| A Study to Evaluate Real World Outcomes of the enVista® Aspire (EA) and Aspire Toric (ETA) Intraocular Lens in Subjects Undergoing Cataract Extraction enVista Aspire EA or Aspire Toric ETA IOLs - Cataract | Not applicable | Completed | Bausch & Lomb Incorporated | 335 | 2024-08-29 | 2026-06-03 |
| Clinical Evaluation of the Performance of the enVista® Aspire™ (EA) Lens enVista® Aspire™, An IOL with a slightly extended depth of focus, MX60E - Cataract | Not applicable | Terminated | Bausch & Lomb Incorporated | 27 | 2024-08-15 | 2026-05-26 |
| Study to Evaluate the Safety and Effectiveness of the enVista® Beyond (EY) EDF Intraocular Lens in Subjects Undergoing Cataract Extraction enVista Beyond EY (EDF) IOL, enVista MX60E monofocal IOL - Cataract | Not applicable | Completed | Bausch & Lomb Incorporated | 304 | 2024-08-07 | 2026-07-13 |
Showing 20 of 279. Sign in to see all of them.
Cataract (41) · Myopia (38) · Dry Eye Syndromes (36) · Astigmatism (21) · Conjunctivitis, Allergic (18) · Inflammation (18) · Pain (12) · Ocular Hypertension (11) · Glaucoma, Open-Angle (7) · Presbyopia (7) · Conjunctivitis, Bacterial (6) · Aphakia (5) · Conjunctivitis (5) · Glaucoma (5) · Macular Degeneration (5)
Loteprednol Etabonate (22) · besifloxacin (14) · Fluocinolone Acetonide (9) · BOL 303259-X (8) · Brimonidine Tartrate (8) · Chondroitinases and Chondroitin Lyases (7) · R-1,1,1-trifluoro-4-(5-fluoro-2,3-dihydrobenzofuran-7-yl)-4-methyl-2-(((2-methyl-5-quinolyl)amino)methyl)pentan-2-ol (7) · bromfenac (7) · bepotastine besilate (6) · Ketotifen (5) · Ophthalmic Solutions (5) · Tobramycin (5) · lifitegrast (5) · perfluorohexyl-octan (5) · BID protein, human (4)
United States (218) · Canada (7) · Germany (5) · Philippines (4) · France (3) · Malaysia (3) · Singapore (3) · China (2) · Japan (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Brazil (1) · Honduras (1) · Hong Kong (1)
Tim McNamara, PharmD (17) · Johnson Varughese (11) · Anya Loncaric (9) · Lisa R Grillone, PhD (7) · Laura Trusso (6) · Robert Steffen, OD, MS (6) · Jeffery Schafer, OD (5) · Bev Barna (4) · Beverly J Barna, CCRA (4) · Daniel Donatello (4) · Quintus Ngumah, OD, PhD (4) · Timothy Comstock, OD (4) · Beverly Barna (3) · Gerard Cairns, MCOptom, PhD (3) · Glenn J Jaffe, MD (3)
PMID 20629472, PMID 32841261, PMID 18441312, PMID 21751945, PMID 22991696, PMID 24136301, PMID 29194198, PMID 39564145, PMID 10801969, PMID 11097601, PMID 11470690, PMID 11594942, PMID 11594943, PMID 11925463, PMID 15136320, PMID 15534261, PMID 15745770, PMID 15808240, PMID 15829793, PMID 16371775, PMID 16603465, PMID 16606880, PMID 16690128, PMID 16877067, PMID 17502507, PMID 17846363, PMID 18062846, PMID 18201681, PMID 18387407, PMID 18387408, PMID 18577309, PMID 18695101, PMID 18779477, PMID 18779490, PMID 19056078, PMID 19323612, PMID 19393842, PMID 19395036, PMID 19508997, PMID 19724216, PMID 19843481, PMID 20065212, PMID 20065219, PMID 20079922, PMID 20457949, PMID 20488431, PMID 20642205, PMID 21383946, PMID 21397770, PMID 21555600
U10EY012358 (1), U10EY012728 (1), U10EY013272 (1)